CEDARHURST, N.Y., Feb. 01, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues
the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in
these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff
and a preliminary estimate of their recoverable losses.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by
the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a
settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from
investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff
and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is
not required to partake in any recovery.
The Goldman Sachs Group, Inc. (NYSE: GS)
A class action has commenced on behalf of shareholders in The Goldman Sachs Group, Inc. who purchased shares between February 28,
2014 and December 17, 2018. The filed complaint alleges that defendants made materially false and/or misleading statements and/or
failed to disclose that: (1) Goldman Sachs participated in a fraud and money-laundering scheme in collusion with 1Malaysia
Development Bhd., a Malaysian state-owned investment fund; (2) the foregoing conduct, when revealed, would foreseeably subject
Goldman Sachs to heightened regulatory investigations and enforcement; and (3) as a result, Goldman Sachs’s public statements were
materially false and misleading at all relevant times.
Shareholders may find more information at https://kseclaw.com/securities/the-goldman-sachs-group-inc/?wire=3
Dentsply Sirona, Inc. (NASDAQ: XRAY)
A class action has commenced on behalf of shareholders in Dentsply Sirona, Inc., including (i) all persons who purchased the common
stock of Dentsply Sirona, Inc. (NASDAQ: XRAY) between February 20, 2014 and August 7, 2018; (ii) all Dentsply International Inc.
shareholders who held shares as of the record date of December 2, 2015 and were entitled to vote with respect to the Acquisition at
the January 11, 2016 special meeting of Dentsply International Inc. shareholders; and (iii) all persons who purchased or otherwise
acquired the common stock of Dentsply International in exchange for their shares of common stock of Sirona in connection with the
Acquisition.
According to the complaint, during the Class Period, Defendants attributed the Company’s financial performance to the Company’s
“innovation,” “operational improvement efforts,” “new products,” and “continued investments in sales and marketing” and told
investors that these factors helped the Company succeed despite the “highly competitive” market for its products. In reality, the
Company’s financial results had been buoyed by an anticompetitive scheme among the Company’s three primary distributors that
suppressed competition in the dental supply market and artificially inflated the price of dental supplies sold by Dentsply.
Further, Defendants concealed that an exclusive distribution arrangement that Sirona had with one of its distributors, Patterson
Companies, Inc. (“Patterson”), required Patterson to regularly make large minimum purchases regardless of demand and, as a result,
by 2015, Patterson had been supplied with so much excess inventory that it could not be sold. This channel-stuffing rendered the
Company’s reported sales, financial results and guidance materially false and misleading. In addition, the Company
represented that it reported its financial statements, including its goodwill, in accordance with generally accepted accounting
principles, or GAAP. In fact, the Company’s reported goodwill was artificially inflated and not reported in accordance with GAAP
because it did not reflect the financial impact of the anticompetitive scheme.
Shareholders may find more information at https://kseclaw.com/securities/dentsply-sirona-inc/?wire=3
NVIDIA Corporation (NASDAQGS: NVDA)
A class action has commenced on behalf of shareholders in NVIDIA Corporation who purchased shares between August 10, 2017 and
November 15, 2018. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to
disclose that: (i) NVIDIA’s growth in its gaming GPU revenue was driven, as repeatedly denied by Defendants, in significant part by
the spiked demand for those GPUs among cryptocurrency miners; (ii) NVIDIA did not have, as Defendants asserted, visibility into its
inventory channel; (iii) NVIDIA was unable to adapt to the volatility of cryptocurrency markets; (iv) as cryptocurrency prices
dropped, NVIDIA hid halting growth from cryptocurrency miners by continuing to push mid-range GPUs into the channel; (v) this would
foreseeably cause an oversupply of gaming card inventory levels on the market and ultimately lead to over three months of excess
inventory in NVIDIA’s channel; and (vi) as a result, NVIDIA’s public statements were materially false and misleading at all
relevant times.
Shareholders may find more information at https://kseclaw.com/securities/nvidia-corporation/?wire=3
Allergan plc (NYSE: AGN)
A class action has commenced on behalf of shareholders in Allergan plc who purchased shares between May 9, 2017 and December 19,
2018. During the Class Period, and unbeknownst to investors, Allergan misled investors regarding various “pharma and device
approvals” and concealed the fact that the Company’s CE Mark for its textured breast implants and tissue expanders was expiring in
Europe.
On December 19, 2018, the Company announced that, following a compulsory recall request from Agence Nationale de Sécurité du
Médicament (“ANSM”), the French regulatory authority, the Company had suspended the sale of these products and that it was
withdrawing all remaining supplies from European markets. The suspension of sales stemmed directly from the expiration of the
company's CE Mark for these products, and the stock price fell drastically following the news.
Shareholders may find more information at https://kseclaw.com/securities/allergan-plc/?wire=3
Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in
good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading
statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.
CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 334
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967
